Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues [Abstract]
Collaboration revenue	$ 763	$ 763
Other revenue	2,964	3,331
Total revenue	22,980	18,860
Operating expenses
Research and development	13,800	8,118
Selling, general and administrative	30,815	12,809
Total operating expenses	56,267	27,172
Loss from operations	(33,287)	(8,312)
Other income (expense)
Interest income and other, net	206	2
Interest expense	0	(1,174)
Change in fair value of warrant liabilities	12,640	0
Change in fair value of earn-out liability	16,462	0
Total other income (expense)	29,308	(1,172)
Net loss	(3,979)	(9,484)
Other comprehensive loss
Net unrealized loss on available-for-sale securities	(652)	(6)
Foreign currency translation gain (loss)	(3)	1
Total other comprehensive loss	(655)	(5)
Comprehensive loss	$ (4,634)	$ (9,489)
Net loss per share, basic (in dollars per share)	$ (0.02)	$ (0.08)
Net loss per share, diluted (in dollars per share)	$ (0.02)	$ (0.08)
Weighted-average shares outstanding, basic (in shares)	182,050,468	114,475,401
Weighted-average shares outstanding, diluted (in shares)	182,050,468	114,475,401
Assay services revenue
Revenues [Abstract]
Revenue	$ 18,800	$ 14,573
Operating expenses
Cost of revenue	11,380	6,155
Product revenue
Revenues [Abstract]
Revenue	453	193
Operating expenses
Cost of revenue	$ 272	$ 90